As the HL7® FHIR® Accelerator focused on transforming the exchange of health data in cancer, cardiovascular health, and genomics, CodeX (Common Oncology Data Elements eXtensions) continues to build momentum through collaboration, innovation, and measurable progress across its community of members and use cases.
Earlier this summer, the Cardiac Implantable Electronic Device (CIED) use case successfully transitioned to the Execution Stage, marking a significant milestone in its advancement through the CodeX Use Case Methodology. In May, the team completed an HL7 off-cycle Connectathon that tested nine use cases with participation from four manufacturers, four software vendors, and two hospitals. All nine scenarios were successfully tested, identifying valuable refinements for the implementation guide (IG), which was balloted in September 2025. This progress reflects CodeX’s continued success in supporting real-world, interoperable device data exchange.
Building on that momentum, two additional use cases, Molecular Tumor Board (MTB) and Pathogen Genomics, have officially entered the planning stage. The Molecular Tumor Board use case focuses on improving how genomic and clinical data are shared to support multidisciplinary tumor board discussions and precision oncology care. The Pathogen Genomics use case aims to enable interoperable data exchange for infectious disease surveillance and One Health applications. Together, these initiatives demonstrate how FHIR continues to expand beyond traditional clinical boundaries, connecting oncology, genomics, and public health data to advance research and care.
In September, CodeX also celebrated the completion of the Risk Evaluation and Mitigation Strategies (REMS) use case. This initiative demonstrated how FHIR-based workflows can streamline communication between prescribers, pharmacists, and patients, improving medication safety and compliance. The REMS team also successfully balloted its implementation guide in September 2025, paving the way for new efforts that will build on these learnings to enhance other high-impact medication safety and regulatory workflows.
Alongside these technical achievements, CodeX continues to grow its diverse membership of healthcare organizations, technology vendors, pharmaceutical manufacturers, research institutions, medical device manufacturers and government agencies. Each new member brings valuable expertise and unique perspectives that strengthen CodeX’s ability to deliver scalable, real-world solutions across oncology, genomics and cardiovascular domains. This growing collaboration within and beyond the HL7 community underscores a shared commitment to advancing interoperability and improving health outcomes.
To keep the broader community informed, CodeX publishes a bi-monthly newsletter on LinkedIn highlighting key milestones, member spotlights, and opportunities to get involved. Readers are encouraged to subscribe and share updates within their networks to help expand awareness and engagement across the HL7 ecosystem. In addition, CodeX maintains an open public calendar listing all upcoming community meetings and conferences, providing an open door for anyone interested in learning, collaborating, or contributing to the future of interoperable data exchange.
As CodeX moves forward, its expanding portfolio, engaged membership, and cross-sector collaboration continue to strengthen the foundation for data interoperability. Through the collective expertise of its community and a shared vision for improving patient care, research, and public health, CodeX remains at the forefront of demonstrating how HL7 FHIR standards can create real, lasting impact across healthcare.
